{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:30:47Z","timestamp":1780713047311,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,10,21]],"date-time":"2009-10-21T00:00:00Z","timestamp":1256083200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s00296-009-1170-6","type":"journal-article","created":{"date-parts":[[2009,10,20]],"date-time":"2009-10-20T10:00:58Z","timestamp":1256032858000},"page":"1459-1463","source":"Crossref","is-referenced-by-count":26,"title":["Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis"],"prefix":"10.1007","volume":"30","author":[{"given":"Tulin","family":"Cagatay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munevver","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sule","family":"Sunmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penbe","family":"Cagatay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziya","family":"Gulbaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Art\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeki","family":"Kilicaslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,21]]},"reference":[{"key":"1170_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/1529-0131(200102)45:1<101::AID-ANR90>3.0.CO;2-7","volume":"45","author":"WP Arend","year":"2001","unstructured":"Arend WP (2001) Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 45:101\u2013106","journal-title":"Arthritis Rheum"},{"issue":"suppl 3","key":"1170_CR2","first-page":"iii17","volume":"43","author":"AL Weaver","year":"2004","unstructured":"Weaver AL (2004) The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology 43(suppl 3):iii17\u2013iii23","journal-title":"Rheumatology"},{"key":"1170_CR3","unstructured":"Kvien TK, Mikkelsen K, Nordvag B et al (2004) Effectiveness of TNF-blocking agents compared to traditional DMARD regimens in patients with rheumatoid arthritis (RA)\u2014a longitudinal observational study. In: Annuala European Congress of Rheumatology EULAR 2004"},{"key":"1170_CR4","unstructured":"de Vries-Bouwstra JK (2003) Clinical and radiological outcomes after one-year follow-up of the best study, a randomized trial comparing four different treatment strategies in early rheumatoid arthritis (RA). In: ACR annual scientific meeting 2003"},{"key":"1170_CR5","unstructured":"Food and Drud Administration, Center for Biologics Evaluation and Research (2001) Safety update on TNF-\u03b1 antagonists: infliximab and etanercept. In: Arthritis advisory committee meeting, 17 August 2001"},{"key":"1170_CR6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0025-6196(11)62418-X","volume":"76","author":"M Baghai","year":"2001","unstructured":"Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL (2001) Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 76:653\u2013656","journal-title":"Mayo Clin Proc"},{"key":"1170_CR7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associted with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med 345:1098\u20131104","journal-title":"N Engl J Med"},{"key":"1170_CR8","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"J Juan","year":"2003","unstructured":"Juan J, Gomez R, Loreto C et al (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 48:2122\u20132127","journal-title":"Arthritis Rheum"},{"key":"1170_CR9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","volume":"50","author":"W Frederick","year":"2004","unstructured":"Frederick W, Kaleb M, Janice A, Urbansky K (2004) Tuberculosis infection with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50:372\u2013379","journal-title":"Arthritis Rheum"},{"key":"1170_CR10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","volume":"39","author":"K Aparna","year":"2004","unstructured":"Aparna K, Timothy R, Joel A, Augustine M, Jeffrey N (2004) Tuberculosis following use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39:295\u2013299","journal-title":"Clin Infect Dis"},{"key":"1170_CR11","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1128\/IAI.70.8.4591-4599.2002","volume":"70","author":"KO Kisich","year":"2002","unstructured":"Kisich KO, Higgins M, Diamond G, Heifets L (2002) Tumor necrosis factor-alpha stimulates killing of Mycobacterium tuberculosis by human neutrophiles. Infect Immun 70:4591\u20134599","journal-title":"Infect Immun"},{"key":"1170_CR12","first-page":"379","volume":"79","author":"H Koneko","year":"1999","unstructured":"Koneko H, Yamada H, Mizuno S, Udagawa T, Kazumi Y, Sekikawa K et al (1999) Role of tumor necrosis factor-alpha in Mycobacterium induced granuloma formation in tumor necrosis factor-alpha deficient mice. Lab Invest 79:379\u2013386","journal-title":"Lab Invest"},{"key":"1170_CR13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","volume":"56","author":"V Kindler","year":"1989","unstructured":"Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731\u2013740","journal-title":"Cell"},{"key":"1170_CR14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/rheumatology\/kei103","volume":"44","author":"J Ledingham","year":"2005","unstructured":"Ledingham J, Wilkinson C, Deighton C (2005) British Thorasic Society (BTS) recommendations for assesing risk and managing tuberculosis in ptients due to start anti TNF-\u03b1 treatments. Rheumatology 44:1205\u20131206","journal-title":"Rheumatology"},{"key":"1170_CR15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.imlet.2006.08.002","volume":"107","author":"M Vukmanovic-Stejic","year":"2006","unstructured":"Vukmanovic-Stejic M, Reed JR, Lacy KE et al (2006) Mantoux test as a model for a secondary immune response in humans. Immunol Lett 107:93\u2013101","journal-title":"Immunol Lett"},{"key":"1170_CR16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02715694","volume":"3","author":"MG Helliwell","year":"1984","unstructured":"Helliwell MG, Panayi GS, Unger A (1984) Delayed cutaneous hypersensitivity in rheumatoid arthritis:the influence of nutrition and drug therapy. Clin Rheumatol 3:39\u201345","journal-title":"Clin Rheumatol"},{"key":"1170_CR17","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/art.11301","volume":"48","author":"T Ellerin","year":"2003","unstructured":"Ellerin T, Rubin RH, Weinblatt ME (2003) Infections and anti tumor necrosis factor alpha therapy. Arthritis Rheum 48:3013\u20133022","journal-title":"Arthritis Rheum"},{"key":"1170_CR18","first-page":"s221","volume":"61","author":"American Thoracic Society","year":"2000","unstructured":"American Thoracic Society (2000) Targetted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 61:s221\u2013s247","journal-title":"Am J Respir Crit Care Med"},{"key":"1170_CR19","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/ar1994","volume":"8","author":"H Hamdi","year":"2006","unstructured":"Hamdi H, Mariette X, Godot V et al (2006) The RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8:R114","journal-title":"Arthritis Res Ther"},{"key":"1170_CR20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/IAI.58.1.269-271.1990","volume":"58","author":"IEA Flesch","year":"1990","unstructured":"Flesch IEA, Kaufmann SHE (1990) Activation of tuberculostatic macrophage functions by interferon gamma, interleukin 4 and tumor necrosis factor. Infect Immun 58:269\u2013271","journal-title":"Infect Immun"},{"key":"1170_CR21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0966-842X(00)88864-2","volume":"3","author":"LE Bermudez","year":"1995","unstructured":"Bermudez LE, Kaplan G (1995) Recombinant cytokines for controlling mycobacterial infections. Trends Microbiol 3:22\u201327","journal-title":"Trends Microbiol"},{"key":"1170_CR22","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/clinids\/17.6.968","volume":"17","author":"RE Huebner","year":"1993","unstructured":"Huebner RE, Schein MF, Bass JBJ (1993) The tuberculin skin test. Clin Infect Dis 17:968\u2013975","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1170_CR23","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","volume":"64","author":"D Ponce de Leon","year":"2005","unstructured":"Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A et al (2005) Attenuatd response to purified protein derivative in patients with rheumatoid arthritis: study population with a high prevalence of tuberculosis. Ann Rheum Dis 64(9):1360\u20131361","journal-title":"Ann Rheum Dis"},{"key":"1170_CR24","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1001\/jama.293.22.2785","volume":"293","author":"CC Whalen","year":"2005","unstructured":"Whalen CC (2005) Diagnosis of latent tuberculosis infection. JAMA 293:2785\u20132787","journal-title":"JAMA"},{"key":"1170_CR25","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s10067-007-0591-4","volume":"26","author":"I Hanta","year":"2007","unstructured":"Hanta I, Ozbek S, Kuleci S et al (2007) Isoniazid intervention for latent tuberculosis among 86 patients with rheumatological disease administered with anti-TNF\u03b1. Clin Rheumatol 26:1867\u20131870","journal-title":"Clin Rheumatol"},{"issue":"10","key":"1170_CR26","first-page":"1127","volume":"10","author":"L Sichletidis","year":"2006","unstructured":"Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D (2006) Tuberculosis in patients receiving anti-TNF agents despite chemopropylaxis. Int J Tuber Lung Dis 10(10):1127\u20131132","journal-title":"Int J Tuber Lung Dis"},{"key":"1170_CR27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","volume":"39","author":"AK Mohan","year":"2004","unstructured":"Mohan AK, Cote TR, Block JA et al (2004) Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39:295\u2013299","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1170_CR28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/030097402317255372","volume":"31","author":"L Mayardomo","year":"2002","unstructured":"Mayardomo L, Marenco JL, Gomez-Mateos J et al (2002) Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol 31(1):44\u201345","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"1170_CR29","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"J Askling","year":"2003","unstructured":"Askling J, Fored CM, Brandt L et al (2003) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis antagonists in Sweden. Arthritis Rheum 48(8):2122\u20132127","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-009-1170-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-009-1170-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-009-1170-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T04:14:06Z","timestamp":1590207246000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-009-1170-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,21]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1007\/s00296-009-1170-6","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,21]]}}}